European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 247

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 247

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. The data stated that expansion of the market in emerging countries is due to factors such as the rising success rate of RNA-based COVID-19 vaccines, regulatory approval, as well as demand for personalised medicines.

Vaccines 98

Vaccines 98

Express Pharma

DECEMBER 18, 2024

Additionally, the industry is set to make notable progress in cutting-edge areas such as CAR-T cell therapy, mRNA vaccines, and the development of complex molecules, which hold immense potential for driving future growth. Indian pharma market is expected to move up to USD 120-130 Billion by 2030 from current size of USD 58 Billion.

Biosimilars 98

Biosimilars Vaccines 98

The Guardian - Pharmaceutical Industry

APRIL 7, 2023

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives ‘A silver lining’: how Covid ushered in a vaccines golden era Millions of lives could be saved by a groundbreaking set of new vaccines for a range of conditions including cancer, experts have said.

Vaccines 111

Vaccines 111

Express Pharma

AUGUST 27, 2024

Bharat Biotech (BBIL) has launched HILLCHOL (BBV131), an oral cholera vaccine developed under license from Hilleman Laboratories. To meet global demand, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of the vaccine annually.

Vaccines 111

Vaccines 111

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

Express Pharma

DECEMBER 20, 2024

Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Biosimilars 103

Biosimilars Vaccines 103

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunity Immunization Documentation 98

European Pharmaceutical Review

JULY 12, 2023

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Vaccines 137

Vaccines Hospitals 137

Express Pharma

NOVEMBER 26, 2024

With the Indian pharma market projected to grow to $ 130 billion by 2030 and $ 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. With exports nearing $27.84 trillion.

Packaging 105

Packaging Biosimilars Pharmaceutical Manufacturing Dosage 105

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunization Immunity 78

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Express Pharma

SEPTEMBER 20, 2023

The free vaccination camps will be run with support of Brihanmumbai Municipal Corporation (BMC). The ‘Stop Rabies’ initiative aligns with India’s National Action Plan for Dog-Mediated Rabies Elimination by 2030. It adopts a two-pronged approach of vaccination and education.

Vaccines 104

Vaccines 104

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunity Immunization Drug Development 111

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. BioNTech to support trial access for cancer immunotherapies Developing an mRNA cancer vaccine In terms of disease indication, melanoma remains the primary focus of advanced mRNA-based therapies, GlobalData reported.

Immunity 110

Immunity Immunization Vaccines 110

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 105

Biosimilars Vaccines 105

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. If successfully developed, this means cancer vaccines could become part of standard care. Signing of this agreement builds on a memorandum of understanding signed in January.

Vaccines 98

Vaccines 98

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Immunity 116

Immunity Immunization Vaccines 116

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunity Immunization Hospitals 145

Express Pharma

JANUARY 9, 2025

The data will serve as a foundation for cutting-edge research and will catalyse innovations in areas such as mRNA-based vaccines, protein manufacturing, and genetic disorder treatments. The Minister also pointed out that India is the largest vaccine producer in the world and the third-largest startup ecosystem.

Vaccines 105

Vaccines Hospitals 105

Express Pharma

JANUARY 4, 2024

The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. It meets 50 per cent of the global demand for various vaccines, 40 per cent of the generic demand in the US, and 25 per cent of all medicine in the UK.

Packaging 111

Packaging Labelling Vaccines 111

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 New types of drugs, such as oral vaccines, will also be formulated as capsules. Insights on the Empty Capsules Global Market to 2030 – Featuring ACG Worldwide, Bright Pharma Caps and Lonza Among Others [Internet]. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines Diabetes 124

Pharmaceutical Technology

JUNE 27, 2022

The international agency had previously set a target of eliminating viral hepatitis by 2030. As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion.

Vaccines 105

Vaccines 105

Express Pharma

NOVEMBER 24, 2023

With objectives laid down during the G20 presidency, the industry in India is poised to scale to $65 billion by 2024 and surpass $130 billion by 2030, driven by heightened pharma innovation, technological advancements, and a focus on breakthrough products.

Packaging 105

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 105

Express Pharma

JUNE 14, 2024

It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. India’s pharmaceutical industry is a global powerhouse.

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing Packaging 110

pharmaphorum

MAY 11, 2022

If approved, nirsevimab would provide a new option for managing RSV, ahead of the possible rollout of vaccines that could be used to protect young children. Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year.

Vaccines 64

Vaccines 64

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

Express Pharma

MAY 7, 2024

The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Vaccines Drug Pricing 105

Express Pharma

JULY 15, 2024

We believe that implementing a fresh PLI scheme for vaccines and biopharmaceutical raw materials is vital now to put the focus back on value-added domestic production with India-for-India and India-for-the-world production. This would stimulate new investments in both R&D and production initiatives.

Medical Records 105

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 26

Vaccines Immunity Immunization 26